Back to announcement
20250805_OMED_Laporan Informasi dan Fakta Material_31930249_lamp2.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 3
Page 1
INVESTOR BULLETIN COMPANY OVERVIEW
OPERATION UPDATE 1H 2025 PT Jayamas Medica Industri Tbk (OMED), established in
the early 2000s, has grown into a leading player in
Aug 4th 2025 Indonesia’s medical equipment and supplies industry.
OMED’s extensive product portfolio includes approximately
Share Price Data (as of Aug 4, 2025): 3,550 active SKUs, supported by a comprehensive
Ticker on IDX OMED distribution network that reaches 514 cities across all 34
provinces in Indonesia.
Last Closing Price (IDR): 183
COMPANY HIGHLIGHTS
Outstanding Shares: 27,058,850,000
PT Jayamas Medica Industri Tbk (OMED) posted
Market Cap (IDR Bn): 4,952
resilient financial and operational performance in the
first half of 2025, Revenue reached IDR 925.8 billion, up
5.25% from IDR 879.6 billion in 1H24. EBITDA grew to IDR
Shareholder Structure: 195.2 billion with a 21.1% margin, while net profit increased
PT Intisumber Hasilsempurna (%): 83.30 to IDR 154.7 billion, with a slight margin improvement to
16.7%. These results were driven by improved operational
Yacobus Jemmy Hartanto (%): 0.93 efficiency and cost management.
Siane Soetanto (%): 0.90 Operationally, OMED recorded a 7.95% YoY growth
Treasury Shares (%): 0.04 in total sales volume, reaching 1.29 billion units in 1H25.
This growth is driven by surging demand in the Diagnostic &
Public (%): 14.84 Equipment segment (+84.87%), as well as robust growth in
Biotech & Lab (+23.98%) and Wound Care (+11.93%),
offsetting a decline in Hospital Furniture (-19.18%).
Contact us: Disposable & Consumables segment, which remains the
company’s sales backbone, also recorded a solid growth of
Corporate Secretary & Investor Relation 6.78%. On pricing, the company maintained a stable ASP
Email: across most segments, with notable increases in Hospital
corporate.secretary@onemed.co.id Furniture (+71.51%) and Walking Aids & Rehab (+6.11%).
ir@onemed.co.id
Export performance was a standout achievement this
Website: period, with a significant YoY increase of 133.4% to IDR 3.3
www.onemed.co.id billion, fueled by strong demand from the United States and
Latin American countries. This achievement reflects OMED’s
readiness to accelerate its international expansion.
Company’s Presence Across Country
Sumatera 1 National Distribution
Center
Kalimantan Sulawesi
23 Branch offices and
warehouses
Maluku
Papua
11 Sales offices
Bali Lombok
Java Flores 28 Omnichannel
Stores
Page 2
Turning Global Trade Shifts into Long-Term Opportunity
The shift in global trade patterns—driven by U.S. efforts to
Tariff Comparison diversify supply chains away from China—has turned
(Exports to U.S.) Southeast Asia into a strategic sourcing hub for medical
consumables. Indonesia stands out within the region due to
Indonesia 19% its political stability, mature manufacturing ecosystem, and
recently standardized 19% tariff rate, which now applies
Cambodia 19% uniformly across key ASEAN exporters. This creates a more
predictable and competitive trade landscape for
Thailand 19% companies looking to scale exports to the U.S. market.
Malaysia 19% OMED is well-positioned to capture this momentum. As one
of Indonesia’s largest medical disposables manufacturers, we
Philippines 19%
bring scale, operational maturity, and compliance
readiness—key requirements for U.S. buyers. Our existing
Vietnam 20%
export footprint, combined with 2025 initiatives in validation,
mold development, and capacity expansion, underpins our
Myanmar 40%
strategy to serve rising international demand. Export is not
merely an incremental channel—it is a long-term growth
Laos 40%
engine that aligns with global supply chain realignment and
Source: Reuters, CNA OMED’s next phase of expansion.
While the 0% import tariff may lead to increased entry of U.S. medical devices into Indonesia, OMED is unlikely
to be impacted, as these imports are expected to focus on advanced equipment like MRI and CT scanners—
products that require specialized capabilities not yet widely developed in Indonesia. Our core business in
disposables and consumables (BMHP) remains well-insulated, supported by resilient domestic demand, and
accelerating international traction. As quoted by Bisnis Indonesia, we remain confident that this policy shift will
have minimal effect on our operations. (Read the full article here: Bisnis.com – July 25, 2025)
Building a Strong Domestic Foundation with Scalable and Reliable Operations
While the domestic market remains at the core of our business, OMED continue to strengthen operations
with a dual strategy that includes expanding into global markets. To support this, we focus not only on increasing
production capacity but also on improving efficiency and operational stability. A key part of this strategy is
leveraging our production facility in Batang, Central Java. The Batang facility, which is now operational, covers
35,650 square meters and is dedicated to the production of medical gauze, with an annual capacity of 2 million
square meters. This facility enhances our domestic supply chain, reduces reliance on external resources, and
increases capacity to meet the growing market demand.
Page 3
Operational Highlights Unaudited
Production Price
(in thousand units) 1H 2024 1H 2025 YoY (in IDR) 1H 2024 1H 2025 YoY
Sales Volume Average Selling Price
Disposable & Consumables 754,618 805,795 6.78% Disposable & Consumables 592 567 (4.45%)
Wound Care 168,750 188,676 11.93% Wound Care 812 803 (1.05%)
Antiseptic & Dialysis Fluid 208,877 216,343 3.57% Antiseptic & Dialysis Fluid 473 473 (0.05%)
Diagnostic & Equipment 1,209 2,236 84.87% Diagnostic & Equipment 82,025 47,274 (42.37%)
Walking Aids & Rehab 758 843 11.26% Walking Aids & Rehab 51,344 54,614 6.37%
Biotech & Lab 64,534 80,012 23.98% Biotech & Lab 592 532 (10.06%)
Hospital Furniture 36 29 (19.18%) Hospital Furniture 554,102 715,183 29.07%
Total 1,198,602 1,293,934 7.95%
Source: Company’s Internal Data
Financial Highlights
Revenue (In Billion Rupiah) EBITDA (In Billion Rupiah) Net Profit (In Billion Rupiah)
1,886
1,739 1,737
5.3%
25.0%
20.7% 21.6% 21.4% 21.1% 16.8% 17.2% 16.5% 16.7%
879.6 925.8 14.9%
434.6
359.5 407.3 290.5 259.4 324.0
188.3 195.2 145.2 154.7
2022 2023 2024 1H24 1H25 2022 2023 2024 1H24 1H25 2022 2023 2024 1H24 1H25
Revenue Growth EBITDA EBITDA Margin Net Profit Net Profit Margin
Assets (In Billion Rupiah) Liabilities (In Billion Rupiah) Equity (In Billion Rupiah)
2,826 2,837
2,507 2,581 2,496 2,548
2,245
2,069
1,726 466 437
438 330 289 1,245
2021 2022 2023 2024 1H25 2021 2022 2023 2024 1H25
2021 2022 2023 2024 1H25
Source: Company’s Financial Statement
Names mentioned 4 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Intisumber Hasilsempurna
p.1
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.